Kacker Mayank, Vashisht Rohit, Menon Anil S
Department of Medicine, INHS Asvini, Mumbai, Maharashtra, India.
Department of Medicine, Armed Forces Medical College, Pune, Maharashtra, India.
Indian J Sex Transm Dis AIDS. 2023 Jan-Jun;44(1):15-19. doi: 10.4103/ijstd.ijstd_121_22. Epub 2023 Jun 6.
Treatment of people living with human immunodeficiency virus (HIV) (PLHIV) is monitored using plasma HIV viral load levels and CD4 counts. Patients with either immunological nonresponse (virological suppression achieved) or virological nonresponse (immune reconstitution achieved) are termed as having a discordant response. These patients are at higher risk for acquired immunodeficiency syndrome (AIDS)-related infections/diseases/neoplasms, non-AIDS-related illnesses (cardiovascular, neurological, renal, hepatic diseases), and all-cause death. This study was conducted to assess the prevalence of immunovirological discordance among PLHIV after completion of at least 1 year of combination antiretroviral therapy (cART) at an antiretroviral therapy (ART) plus center in India and analyze contributory factors.
The study was a retrospective study of PLHIV receiving cART at the ART plus clinic in Western India from January 18 to December 21. Four hundred and ninety-six patients were studied based on sample size calculated and assessed for CD4 and viral load response at 0, 6, and 12 months of ART.
Of the 496 patients, 48 patients (9.7%) had immunovirological discordance. Out of them, 36 patients (75%) had a virological response (immunological nonresponse) and 12 (25%) patients had an immunological response (virological nonresponse). The factors contributing to immunological nonresponse were as follows - low baseline CD4 levels (<100 cells) (36.1%), adherence <95% (33.3%), presence of opportunistic infections (16.6%), and failure on first-line therapy (11.1%). Other factors noted included higher baseline viral load (2.7%), chronic kidney disease (5.5%), and chronic hepatitis B virus co-infection (5.5%). Virological nonresponse was associated with poor adherence to therapy <95% (33%) and failure of first-line regimen (33%). Opportunistic infections were noted among 33% of patients and 8.3% of patients were found to have higher baseline viral load.
Immunovirological discordance is an important factor influencing response to cART and is associated with many complications such as AIDS and non-AIDS-related events and even death. Improved adherence and timely identification and management of opportunistic infections are measures that are beneficial in reducing the incidence of immunovirological discordance.
使用血浆人类免疫缺陷病毒(HIV)病毒载量水平和CD4细胞计数来监测人类免疫缺陷病毒感染者(PLHIV)的治疗情况。免疫无反应(实现病毒学抑制)或病毒学无反应(实现免疫重建)的患者被称为有不一致反应。这些患者发生获得性免疫缺陷综合征(AIDS)相关感染/疾病/肿瘤、非AIDS相关疾病(心血管、神经、肾脏、肝脏疾病)以及全因死亡的风险更高。本研究旨在评估印度一家抗逆转录病毒治疗(ART)加护中心至少接受1年联合抗逆转录病毒治疗(cART)的PLHIV中免疫病毒学不一致的患病率,并分析相关因素。
该研究是一项对2018年1月至2021年12月期间在印度西部ART加护诊所接受cART的PLHIV的回顾性研究。根据计算的样本量对496例患者进行研究,并在ART开始后的0、6和12个月评估其CD4和病毒载量反应。
在496例患者中,48例(9.7%)存在免疫病毒学不一致。其中,36例(75%)有病毒学反应(免疫无反应),12例(25%)有免疫反应(病毒学无反应)。导致免疫无反应的因素如下——基线CD4水平低(<100个细胞)(36.1%)、依从性<95%(33.3%)、存在机会性感染(16.6%)以及一线治疗失败(11.1%)。其他注意到的因素包括较高的基线病毒载量(2.7%)、慢性肾脏病(5.5%)和慢性乙型肝炎病毒合并感染(5.5%)。病毒学无反应与治疗依从性差<95%(33%)和一线治疗方案失败(33%)有关。33%的患者存在机会性感染,8.3%的患者基线病毒载量较高。
免疫病毒学不一致是影响cART反应的一个重要因素,并且与许多并发症相关,如AIDS和非AIDS相关事件甚至死亡。提高依从性以及及时识别和管理机会性感染是有助于降低免疫病毒学不一致发生率的措施。